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Neurocognitive (NC) impairment remains prevalent among people living with HIV (PLWH)
and may be exacerbated by alcohol and drug use. This cross-sectional study assesses the
degree to which alcohol and other drug use, time from HIV diagnosis to treatment, and
years living with HIV affect three areas of NC functioning among HIV-seropositive adults.
NC functioning in 370 PLWH living in Miami, FL was assessed using the Auditory Verbal
Learning Test, the Short Category Test, Booklet Format, and the Color Trails Test 2 (CTT2).
Participants reported the number of days using alcohol, marijuana, and cocaine over the
previous 3 months, the number of known years living with HIV and length of time from
HIV diagnosis to seeking care. Bivariate linear regression and multivariate linear regres-
sion were used to test associations between independent and dependent variables. Mean
scores on NC measures were significantly lower than published norms; 39% of participants
scored ≥1 standard deviation below normative sample means on >2 NC tests. No signifi-
cant associations were found between alcohol or cocaine use and any NC measure. Years
living with HIV was associated with CTT2 in the bivariate analysis (β=1.031; p=0.007). In
multivariate analysis, each day of marijuana use and years living with HIV were associated
with a 0.32 (p=0.05) point and 1.18 (p= 0.03) points poorer performance score on the
CTT2, respectively. Results suggest that both marijuana use and duration of HIV infection
may affect cognitive functioning among PLWH in ways that may impair their ability to follow
important treatment guidance.
Keywords: HIV, neurocognitive, alcohol, marijuana, ColorTrailsTest
INTRODUCTION
Since the introduction of highly active antiretroviral treatment
(ART), the incidence of HIV-associated dementia has declined
from 10 to 15% to rates of 2–5% in people living with HIV (PLWH)
(1–3). However, milder forms of HIV-associated neurocognitive
disorders (HAND) continue to be reported in up to 40% of this
population, in part because HIV-positive individuals are living
longer with the disease (4–8).
HAND, ranging from mild impairment to profoundly dis-
abling HIV-associated dementia (7), is mostly seen in advanced
stages of HIV disease but can occur even in PLWH who
have medically asymptomatic HIV infection (9–11). While
increased time living with the virus, particularly during the
acute phase of HIV infection, is associated with neurocogni-
tive (NC) impairment, HAND has been observed even among
PLWH who have consistently maintained low-to-undetectable
viral loads on ART (12, 13). Early initiation of ART is known
to reduce the risk of developing HAND (14, 15). At the
time of this study, treatment guidelines recommended that
all HIV-infected adults with a CD4 count of <350 be pre-
scribed ART.
HAND can express clinically as impairment in episodic mem-
ory, information processing, attention, and executive functions
(16). In patients presenting with even milder forms of HAND,
quality of life can be greatly affected, with individuals suffering
from difficulties in ability to perform activities of daily living,
personal health care management, medication management, and
risk behavior reduction (6, 17, 18). Mild or asymptomatic NC
impairment is known to be more prevalent than the more debili-
tating HAND diagnoses (19, 20); however, even when NC impair-
ment is asymptomatic, HAND may still be associated with func-
tional problems such as poorer employment capacity and lower
symptom reporting related to lower self-awareness (1, 19, 21).
Abuse of alcohol and other drugs frequently co-occurs with
HIV and may further impair NC functioning (22, 23). HIV infec-
tion and heavy drug or alcohol use have been observed to have
synergistically negative effects on NC functioning and the pro-
gression of HAND (24–26). Impaired verbal and auditory working
memory, and enhanced cognitive impulsivity have been observed
(27, 28). These cognitive functions are associated with the higher-
order thinking required to conduct safer sex practices and health
management behaviors such as ART adherence (17, 24, 29, 30).
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It is important to understand specific domains of impairment
associated with exposure to HIV and the use of commonly abused
substances such as alcohol, marijuana, and cocaine in order to
deliver targeted and effective clinical care, as well as HIV risk
reduction and treatment adherence interventions. Using struc-
tural equation modeling (SEM), this study sought to identify direct
relationships between exposure to HIV and degree of alcohol and
drug use upon several major domains of NC functioning including
memory, information processing, attention, and executive func-
tion. It was expected that longer time living with HIV, longer time
from HIV diagnosis to seeking care, and greater use of substances
would reduce performance on several NC measures. Outcomes
may help identify areas of cognitive functioning affected by sub-
stance abuse and HIV in order to improve ways in which health
care information is delivered by clinicians and retained by patients.
MATERIALS AND METHODS
STUDY DESIGN
This study employed a cross-sectional design, utilizing baseline
data gathered between 2009 and 2012 as part of a prospective
randomized controlled trial for HIV-positive adult alcohol users.
Participants (N = 370) were recruited from 13 community-based
organizations (CBOs) in densely populated, multicultural, low-
income, urban areas of South Florida, primarily Miami-Dade
County, with high rates of substance abuse, HIV, violence, and
poverty. The CBOs were among the largest in the local area pro-
viding substance abuse treatment (inpatient or outpatient) and
mental health services to HIV-positive men and women. Recruit-
ment settings were selected from a wide range of non-academic
institutions, specialty and primary care, public and private facili-
ties; however, 23.5% of participants were in residential substance
abuse treatment at the time of data collection. The inclusion cri-
teria were: being 18 to 60-years-old; being HIV-positive; having
consumed any alcohol in the past 3 months; having a history
of alcohol abuse or dependence within the past 2 years; facility
in English; and currently not showing overt signs of any major
psychiatric disorder. Participants in the parent study were ran-
domized to a group level, 8-week intervention to reduce substance
abuse, and sex risk among PLWH or to a similarly administered
health comparison group providing standard of care content. The
research protocol was approved by the Institutional Review Board
of Florida International University and all participants provided
signed informed consent prior to participating in the study.
Assessment methods consisted of: (1) computer-assisted
personal interview (CAPI); (2) audio computer-assisted self-
interview for subjective sensitive topics (ACASI); (3) paper and
pen as specified for neurological measures; and (4) Timeline
Follow-Back (TLFB).
MEASURES
“Years living with HIV” was measured by asking the year, they
received their first HIV-positive test. This value was subtracted
from the year of intake to calculate number of years living
with HIV.
Time from HIV diagnosis to seeking medical care was an ordi-
nal item from the Community Programs for Clinical Research on
AIDS [CPCRA; (31)] asking “How soon after your positive test for
HIV did you first go for medical care for your HIV?” Response
options were: (1) within 6 weeks; (2) 6–12 weeks; (3) 3–6 months;
(4) 6–12 months; (5) more than a year; and (6) I have not gone
for medical care for my HIV. This final response option did not
provide an interval time measurement. Two participants selecting
option (6) had been diagnosed at least 1 year before interview and
were classified as option (5) and one participant had been diag-
nosed recently so this response was coded as“missing.”It should be
noted that this question did not ask when treatment was initiated,
only when it was sought.
Alcohol, marijuana, and cocaine use were assessed by TLFB to
provide a continuous 3 months history for intensity of drug and
alcohol consumption. These variables were measured: total num-
ber of “heavy drinking days” (defined as≥5 drinks), total number
of marijuana use days, and total number of cocaine use days. Up to
3 months recall of alcohol and other drug use has proven to yield
reliable data (32). TLFB has strong agreement with other measures
of substance use and has reliability measures ranging from 0.75 to
0.90 (33).
Three neuropsychological tests were administered to derive
scores in various cognitive domains, selected for importance to
behaviors associated with maintaining health and reducing risk
of transmission among PLWH. For example, information pro-
cessing and memory are related to comprehending, retaining, and
applying instructions such as medical advice and medication dos-
ing (34). The tests selected have been used in previous studies
with HIV-positive users of alcohol, marijuana, and cocaine and
have well-developed norms, high reliability, and high validity (24,
35–39).
Auditory Verbal Learning Test, University of California Los
Angeles/World Health Organization Version
Fifteen words were read to the participant, requesting both imme-
diate and longer-term recall (34, 38). Scores for immediate recall,
delayed recall, and percent of words retained can be derived. This
study utilized the total of immediate recall scores for trials 1–5,
with higher scores indicating greater functioning. This instrument
demonstrated high test-retest reliability, with alpha scores ranging
from 0.51 to 0.72 (34).
The Color Trails Test 2, Form A (CTT2)
CTT-2 shows two sets of 1–25 numbered circles, and using a pen,
the participant must quickly connect the numbers in order, alter-
nating between pink and yellow (34, 40, 41). This analysis used
the raw time in seconds the participant required to complete the
test, with higher scores indicating poorer functioning. The test is
sensitive to a variety of neurological impairments and processes
(42) and, because it is entirely numeric, it is considered cultur-
ally unbiased (36). Additionally, the instrument has shown strong
agreement with other cognitive assessments among PLWH (36, 43)
and has displayed good temporal stability with test-retest reliability
between 0.85 and 1.00 (41).
The Short Category Test booklet format
This assesses problem-solving ability, requiring the examinee to
determine the organizing principle behind a series of visually
presented stimuli, based on external feedback from the test admin-
istrator (44, 45). This study uses the total raw error score derived,
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with higher scores indicating poorer functioning. Test-retest coef-
ficients have varied from 0.60 to 0.96 depending upon the severity
of impairment in the sample (44).
ANALYTIC STRATEGY
A hypothesized directional model was constructed to assess the
degree to which independent relationships exist between HIV
exposure, alcohol use, marijuana use, and cocaine use on the out-
come of NC functioning as indicated by three different cognitive
performance measures.
Means, standard deviations, skewness, and kurtosis levels were
calculated for all continuous variables; frequencies were gener-
ated for dichotomous and categorical variables. In order to gain
an understanding of the overall degree of NC impairment in this
sample, one-sample t -tests were used to compare mean raw NC
scores with normative scores on each instrument. Raw scores
were square root transformed, with confidence intervals repre-
senting the difference between the raw, transformed scores, and
square roots of the normative scores. Norms for NC measures were
obtained from professional manuals provided for the instruments
(41, 46, 47). In addition, using chi-square analysis, participants
were dichotomized – those who scored >1 standard deviation
below the means of normative samples on at least two NC assess-
ments versus those with higher NC performance – and cross
tabulated on whether they reported taking prescribed ART. Raw
NC scores were used in bivariate and multivariate regression analy-
ses; age, gender, and educational level were entered as covariates to
control for their possible impact upon NC scores. Bivariate regres-
sion analyses assessed relationships between each independent and
dependent variable using SPSS version 21. Maximum Likelihood
framework was invoked in MPlus version 5.1 (48) to accommodate
non-normality in the multivariate, SEM analysis (49). Approxi-
mately 8% of data was missing randomly across variables. With
no systematic patterns observed in the missing data, a full infor-
mation maximum likelihood method was used to accommodate
the missing data in the SEM analysis. To assess non-model-based
outliers, leverage indices were examined for each participant based
on their multivariate profile for the variables included in the model
analyses. No observations had a leverage score four times greater
than the mean leverage (0.09) in the sample data. After addressing
all diagnostic statistics, the final hypothesized model was analyzed
using Mplus; strengths of association were reported.
RESULTS
The mean age of participants was 44.79 years; most (63.5%) were
men and identified as black (76.2%). Most (55.7%) of partici-
pants reported at least high school completion; few (8.2%) were
employed. The mean number of years living with HIV was 12.2.
While most (58.4%) sought medical care within 6 weeks of receiv-
ing a positive HIV test, 24.6% of participants waited over a year
before seeking care (Table 1). Although not included in the tested
model, the majority (76.7%) reported that they were currently tak-
ing ART; 80% reported perfect (100%) treatment adherence; and
45% had an undetectable viral load when last tested. Use of mar-
ijuana in this cohort was substantially lower than use of alcohol
and cocaine; however, more than half of all participants reported
some marijuana use.
Table 1 | Sociodemographic characteristics of participants at baseline
(N =370).
Mean (SD)
N (%)
Skewness/
Kurtosis
Age 44.79 (7.3) −0.56/−0.13
Gender (male) 233 (63.5) −0.56/−0.69
Hispanic ethnicity (yes) 53 (15) 1.97/1.90
Race
Black 266 (76.2) −1.24/−0.47
White 50 (14.3) 2.05/2.20
Years education 0.41/−0.17
<HS diploma 157 (44.3) –
≥HS diploma 198 (55.7) –
Employed (Yes) 29 (8.2) 3.07/7.45
Years since HIV diagnosis 12.15 (7.5) 0.20/−1.01
Time from HIV diagnosis to treatment 0.65/−1.41
Within 6 weeks 206 (58.4) –
6–12 weeks 13 (3.7) –
3–6 months 22 (6.2) –
6 months–1 year 25 (7.1) –
1 year+ 87 (24.6) –
Taking ART (yes) 273 (76.7) −1.27/−0.40
Currently in residential substance
treatment
84 (23.5) 0.66/−1.27
Days using in last 3 months
Alcohol 15.77 (23.33) 1.86/2.83
Marijuana 9.29 (20.68) 2.84/7.59
Cocaine 15.68 (23.89) 1.89/2.80
Neurocognitive functioning
CTT2 116.31 (49.82)a 1.71/4.97
SCT 38.09 (15.58)a −0.38/−0.86
AVLT 43.44 (9.63)a −0.03/−0.22
aRaw scores reported. All sample means are significantly different from normative
sample at p<0.01.
Normative scores used for comparison testing represented mean age and educa-
tion for this sample. Skewness and Kurtosis values for neurocognitive instruments
reflect distribution of scores prior to square root transformation.
Single sample t -tests comparing the mean raw NC scores with
normative scores on each instrument showed that performance
for the study group was significantly poorer (all p< 0.001) than
observed in healthy samples as follows: auditory verbal learning
test (AVLT), t =−16.25 [95% CI=−0.67,−0.52]; CTT2, t = 6.65
[95% CI= 0.53, 0.97]; and short category test booklet format
(SCT), t = 11.52 [95% CI= 0.66, 0.93]. Over a third (39%) of the
study population scored at least one standard deviation below the
mean for normative samples on at least two NC tests, consistent
with clinically significant NC impairment (7). No association was
observed between the higher and lower performing groups based
upon whether they reported being on prescribed ART (χ2= 0.021,
p= 0.88).
Bivariate analyses (Table 2) identified one significant relation-
ship: years living with HIV was associated with poorer scores on
the CTT2 (β= 1.031; 95% CI: 0.285, 1.777; p= 0.007). After exam-
ining normality, outliers and patterns of missing data, the final
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Table 2 | Bivariate regression statistics, 95% confidence intervals, and
p-values (N =370).
β 95% CI P
Alcohol daysa AVLTf −0.005 −0.049, 0.039 0.82
CTT2g −0.137 −0.386, 0.111 0.28
SCTh −0.017 −0.089, 0.056 0.65
Marijuana daysb AVLT 0.009 −0.044, 0.063 0.73
CTT2 0.275 −0.024, 0.573 0.07
SCT −0.049 −0.137, 0.038 0.27
Cocaine daysc AVLT 0.011 −0.032, 0.053 0.63
CTT2 −0.172 −0.413, 0.069 0.16
SCT 0.027 −0.033, 0.097 0.46
Years of HIV
infectiond
AVLT −0.075 −0.208, 0.059 0.27
CTT2 1.031 0.285, 1.777 0.007
SCT 0.096 −0.124, 0.316 0.39
Time from HIV
diagnosis to seeking
medical caree
AVLT −0.045 −0.570, 0.480 0.87
CTT2 0.384 −2.509, 3.277 0.79
SCT −0.333 −1.192, 0.526 0.447
aNumber of days using alcohol in past 3 months.
bNumber of days using marijuana in past 3 months.
cNumber of days using cocaine in past 3 months.
dDuration of known HIV infection in years.
eTime interval from diagnosis of HIV infection to seeking medical care.
fAuditory Verbal Learning Test.
gColor Trails Test 2.
hShort Category Test.
multivariate model was tested. Figure 1 and Table 3 present sig-
nificant and non-significant unstandardized path coefficients of
the final model. This was a just-identified model (χ2= 0, 0 df;
CFI= 1; RMSEA= 0; SRMR= 0). All exogenous variables were
assumed to be correlated. Unstandardized path coefficients, stan-
dard errors and 95% confidence intervals are listed in Table 3.
Residual error terms across three measures of NC functioning
were correlated. Focused fit indices did not show evidence of Hey-
wood cases. Standardized residual values were<2. The final model
explained 8% of variance in memory, 7% of variance in informa-
tion processing, and 4% of variance in executive functions. In the
final model, two associations approached or achieved statistical
significance. On average, for each day of marijuana use, the CTT2
score increased by 0.32 (p= 0.051), indicating poorer performance
on this NC measure. Similarly, on average, each year living with
HIV increased the CTT2 score by 1.18 (p= 0.03).
DISCUSSION
Neurocognitive impairment was common (39%) in this group;
however, other U.S. studies of HIV-seropositive adults using sim-
ilar NC measures have yielded different results. A U.S. study
of adult PLWH found their participants scored better on CTT2
(x¯ = 100.1) than participants in this study (50). Another study
of HIV-seropositive African-American men also reported signif-
icantly better CTT2 scores with mean score of 93.09 for their
HIV+ symptomatic group (51). These higher functioning levels
could be explained by their samples’ lower mean age and AOD use
characteristics.
While not all hypothesized associations were supported in
this model, two variables – marijuana use and duration of HIV
infection – were associated with poorer performance on one NC
measure. Albeit marginal, higher number of days of marijuana
use showed some relation with poorer performance on the CTT2,
an instrument that measures frontal systems functioning such as
attention, executive functions, and information processing (41,
52). Although significant differences in CTT2 scores have been
identified between HIV-positive intravenous drug users and non-
users (53), previous research on the NC effects of marijuana use
has yielded mixed results. Most studies examining marijuana-
associated NC functioning found long-term use to impede per-
formance in domains of executive functions, verbal memory, and
psychomotor speed (38, 54, 55). While it is believed that chronic
illicit drug use can exacerbate NC sequelae of HIV infection (25,56,
57), little actual exploration of long-term cognitive impact of mar-
ijuana use has been conducted among PLWH. One study reported
a significant association between marijuana use and poorer NC
functioning among PLWH with more advanced disease, with most
profound effects in the area of memory performance (58).
Methodological issues associated with NC assessment and
effects of marijuana use should be considered when interpreting
these and similar study outcomes (54). In this study, a 3-month
drug use history was collected with no control for any recent period
of drug abstinence; thus, it is possible that NC performance mea-
sures may have also captured intoxication effects of marijuana.
Additionally, only associations with performance on the CTT2
measure were significant; however, this instrument may measure
several domains of functioning, including psychomotor speed
attention (41). Without the corroboration of instruments mea-
suring similar NC domains, the exact areas of neuropsychological
impact associated with marijuana use cannot be determined with
certainty.
An additional finding of this research was that the number
of years living with HIV predicted poorer performance on the
CTT2 instrument; however, no significant association was found
between NC functioning and the length of time from HIV diag-
nosis to seeking care. Although ART has significantly reduced
incidence of severe NC disorders among PLWH, milder HAND
remains common even among virally suppressed patients (59).
In this sample, it should be noted that participants were het-
erogeneous, in varying stages of ART treatment and exhibiting
different degrees of viral suppression. There are several possi-
ble explanations for poorer NC functioning observed among
those living longer with HIV, but not necessarily associated with
delayed ART initiation. An inflammatory response can occur
when immune functioning rebounds after treatment with ART,
known as immune reconstitution inflammatory syndrome (IRIS).
However, regardless of possible IRIS, greater immunosuppression
remains a strong predictor of NC impairment among PLWH (1,
60); thus, early initiation of ART is reported to be one of the most
important preventive measures against developing HAND (13, 61)
and continuous adherence remains a protective factor against NC
impairment (17). While some participants in this study may have
initiated treatment early, only about 77% of participants in this
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FIGURE 1 | Significant regression paths among measured variables in the structural equation model among HIV-positive alcohol abusers (N =370).
Model included age, gender and education level as covariates. Regression coefficients (represented as one-way arrows) are unstandardized. *p<0.05.
group report currently taking ART. It is also possible that the asso-
ciation found between years living with HIV and poorer CTT2
performance may be a function of age-related cognitive decline
(62); although the analyses controlled for age.
Certain limitations of this study are important to note. First,
the tested model was just identified and future studies may seek
to assess models where non-significant paths are trimmed as one
avenue for replicating these study findings. Also, reporting bias
should be considered in interpreting outcomes. Nearly a quar-
ter of the study population was in abstinence-based, residential
addiction treatment at the time of this study, and it is possible
that recent substance use was underreported. Residential treat-
ment status was not a covariate in this model primarily because
all participants had a history of substance use and frequently uti-
lized substance abuse services – both inpatient and outpatient.
While residential treatment status could have been responsible for
underreporting of recent substance use, including this variable in
the model could have created excessive noise. Moreover, underre-
porting may have varied by substance; marijuana use is likely to
be less stigmatized than cocaine use (63) and possibly less than
alcohol use. Measurement issues also should be considered. HIV
or drug/alcohol use can affect other cognitive functions not eval-
uated here, such as prospective memory and cognitive impulsivity
(16, 64, 65). The NC instruments used, however, are commonly
utilized in similar research and considered to be reliable. Of greater
concern is that poor mean NC scores for this group may also sug-
gest poorer recall on self-report measures. In addition, the CTT2
may be non-specific, evaluating several domains of functioning.
Finally, the measurement of time from HIV diagnosis to seeking
care did not provide information on actual time to ART initiation.
For the purpose of this study, the measure was used as a proxy for
ART initiation – i.e., one who sought care sooner might also be
treated with ART sooner.
Counter to reports that cocaine and alcohol use exacerbate NC
impairment among PLWH (24, 26, 66, 67), this particular study
did not find such associations. Because abuse of alcohol and illicit
substances is inextricably linked to HIV (22), further investiga-
tion into interaction effects between long-term drug/alcohol use
and HIV is recommended. Further, future research should con-
sider the contributions of substance use to overall NC functioning
for the delivery of clinical care and health behavior interventions.
Early HIV care can help decrease potential NC impairment and
yield better health outcomes for HIV-infected populations; how-
ever, people suffering from substance use disorders or cognitive
impairment may find it difficult to follow important medical rec-
ommendations (17, 24, 29, 68–70). Outcomes from this study
provide further evidence of the prevalence of NC impairment that
can help to guide and enhance interventions for PLWH who use
alcohol and drugs.
CONCLUSION
Associations found with the CTT2 in particular points to the utility
of this instrument for HAND assessment. In order to deliver effec-
tive health care to PLWH, especially those who use substances, it is
important to understand the areas of functioning most affected by
HAND and potentially incorporate into care remediation strate-
gies that will help improve patient engagement. The delivery of
health interventions and clinical care should consider taking a
harm-reduction approach: working with the patient’s current sub-
stance use status to improve HIV treatment adherence and service
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Table 3 | Multivariate, unstandardized path coefficients, standard
errors, 95% confidence intervals, and p-values (N =370).
Coefficient SE 95% CI P
Alcohol daysa AVLTf −0.01 0.03 −0.07, 0.51 0.79
CTT2g −0.05 0.16 −0.36, 0.26 0.75
SCTh 0.02 0.04 −0.06, 0.11 0.59
Marijuana daysb AVLT 0.03 0.04 −0.05, 0.11 0.45
CTT2 0.32** 0.17 −0.001, 0.65 0.05
SCT −0.01 0.06 −0.13, 0.10 0.82
Cocaine daysc AVLT 0.00 0.03 −0.05, 0.06 0.94
CTT2 −0.13 0.14 −0.40, 0.15 0.37
SCT 0.02 0.05 −0.07, 0.11 0.65
Years of HIV
infectiond
AVLT −0.04 0.10 −0.23, 0.15 0.66
CTT2 1.18* 0.54 0.12, 2.25 0.03
SCT 0.14 0.15 −0.17, 0.44 0.37
Time from HIV
diagnosis to seeking
medical caree
AVLT 0.18 0.38 −0.56, 0.92 0.63
CTT2 −1.77 2.33 −6.34, 2.79 0.45
SCT −0.48 0.61 −1.68, 0.44 0.43
Model included age, gender and education level as covariates.
aNumber of days using alcohol in past 3 months.
bNumber of days using marijuana in past 3 months.
cNumber of days using cocaine in past 3 months
dDuration of known HIV infection in years.
eTime interval from diagnosis of HIV infection to seeking medical treatment.
fAuditory Verbal Learning Test.
gColor Trails Test 2.
hShort Category Test.
*Significant at p<0.05.
**Approaching significance.
utilization and delivering interventions and services that are sen-
sitive to cognitive difficulties (71–73). Finally, it may be advised to
consider including information about HAND into HIV preven-
tion efforts, particularly to encourage testing and early treatment.
It is unclear to date how knowledgeable at risk populations are
about NC effects of HIV; however, growing evidence shows that
NC impairment is lower among PLWH who are treated early (74).
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